Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis

Journal of Rheumatology

Volumn 39, Issue 2, 2012, Pages 352-358

  Hochberg, Marc C ^a   Wohlreich, Madelaine ^b   Gaynor, Paula ^b   Hanna, Sylvia ^c   Risser, Rick ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Lilly USA   (United States)

^c SYNEOS HEALTH   (United States)

Author keywords

Duloxetine; Osteoarthritis; Outcome assessment; Pain

Indexed keywords

DULOXETINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ANOREXIA; ARTICLE; ASTHENIA; CONSTIPATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; HUMAN; HYPERHIDROSIS; KNEE OSTEOARTHRITIS; LIBIDO DISORDER; MINIMAL CLINICAL IMPORTANT IMPROVEMENT; NAUSEA; OUTCOME ASSESSMENT; OUTCOME MEASURES IN RHEUMATOID ARTHRITIS CLINICAL TRIALS OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL; PAIN ASSESSMENT; PATIENT ACCEPTABLE SYMPTOM STATE; POST HOC ANALYSIS; PRIORITY JOURNAL; UPPER ABDOMINAL PAIN;

ADRENERGIC UPTAKE INHIBITORS; AGED; CHRONIC PAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 84856555540     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110307     Document Type: Article

References (45)

1. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): A review of its utility and measurement properties. Arthritis Rheum 2001;45:453-61. (Pubitemid 32979851)
2. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
3. Chapman CR, Casey KL, Dubner R, Foley KM, Gracely RH, Reading AE. Pain measurement: An overview. Pain 1985;22:1-31. (Pubitemid 15037578)
4. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation - value in comparison with other assessment tests. Scand J Rheumatol Suppl 1987;65:85-9.
5. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The Arthritis Impact Measurement Scales. Arthritis Rheum 1980;23:146-52. (Pubitemid 10164319)
6. Pham T, van der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, et al. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648-54. (Pubitemid 36835471)
7. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389-99. (Pubitemid 38594267)
8. Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. Response criteria for clinical trials on osteoarthritis of the knee and hip: A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000;8:395-403. (Pubitemid 32000962)
9. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: The minimal clinically important improvement. Ann Rheum Dis 2005;64:29-33. (Pubitemid 40075270)
10. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: The patient acceptable symptom state. Ann Rheum Dis 2005;64:34-7. (Pubitemid 40075271)
11. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol 2007;34:1188-93. (Pubitemid 46774873)
12. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19. (Pubitemid 40038441)
13. Briley M. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 2003;4:42-5. (Pubitemid 36253677)
14. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol 2004;19 Suppl 1:S21-5. (Pubitemid 39386316)
15. Delgado PL. Common pathways of depression and pain. J Clin Psychiatry 2004;65 Suppl 12:16-9.
16. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18. (Pubitemid 40828506)
17. Pritchett YL, McCarberg BH, Watkin JG, Robinson MJ. Duloxetine for the management of diabetic peripheral neuropathic pain: Response profile. Pain Med 2007;8:397-409. (Pubitemid 47163277)
18. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56. (Pubitemid 41727332)
19. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20. (Pubitemid 44632065)
20. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84. (Pubitemid 39209537)
21. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15. (Pubitemid 41752960)
22. Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF. Duloxetine for the treatment of fibromyalgia in women: Pooled results from 2 randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 2007;16:1145-56. (Pubitemid 47587341)
23. Choy EH, Mease PJ, Kajdasz DK, Wohlreich MM, Crits-Christoph P, Walker DJ, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: Pooled analysis of data from five clinical trials. Clin Rheumatol 2009;28:1035-44.
24. Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum 2010;39:454-64.
25. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44.
26. Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009;16:1041-48.
27. Skljarevski V, Zhang Q, Desaiah D, Alaka KJ, Palacios S, Miazgowski T, et al. Duloxetine versus placebo in patients with chronic low back pain: A 12-week, randomized, double-blind trial. J Pain 2010;11:1282-90.
28. Skljarevski V, Zhang Q, Chappell AS, Walker DJ, Murray I, Backonja M. Maintenance of effect of duloxetine in patients with chronic low back pain: A 41-week, uncontrolled, dose-blinded study. Pain Med 2010;11:648-57.
29. Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010;35:E578-85.
30. Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial. Pain 2009;146:253-60.
31. Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2010;11:33-41.
32. Guy W. ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education, and Welfare publication (ADM). Rockville, MD: National Institute of Mental Health; 1976.
33. Altman DG. Confidence intervals for the number needed to treat. Br Med J 1998;317:1309-12. (Pubitemid 28502420)
34. Sackett DL. On some clinically useful measures of the effects of treatment. Evidence-Based Med 1996;1:37-8. (Pubitemid 126736448)
35. Sackett DL, Deeks JJ, Altman DG. Down with odds ratios! Evidence-Based Med 1996;1:164.
36. Bellamy N, Bell MJ, Goldsmith CH, Pericak D, Walker V, Raynauld JP, et al. The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: An application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI. Osteoarthritis Cartilage 2005;13:104-10. (Pubitemid 40220800)
37. Bingham CO 3rd, Bird SR, Smugar SS, Xu X, Tershakovec AM. Responder analysis and correlation of outcome measures: Pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis. Osteoarthritis Cartilage 2008;16:1289-93.
38. Bingham CO 3rd, Smugar SS, Wang H, Tershakovec AM. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: Pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. Rheumatology 2009;48:1122-7.
39. Chevalier X, Jerosch J, Goupille P, van Dijk N, Luyten FP, Scott DL, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: A randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis 2010;69:113-9.
40. Foster NE, Thomas E, Hill JC, Hay EM. The relationship between patient and practitioner expectations and preferences and clinical outcomes in a trial of exercise and acupuncture for knee osteoarthritis. Eur J Pain 2010;14:402-9.
41. Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: A 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 2005;21:517-26. (Pubitemid 40676103)
42. Mazieres B, Hucher M, Zaim M, Garnero P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: A multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2007;66:639-45. (Pubitemid 46707133)
43. Onel E, Kolsun K, Kauffman JI. Post-hoc analysis of a head-to-head hyaluronic acid comparison in knee osteoarthritis using the 2004 OMERACT-OARSI responder criteria. Clin Drug Investig 2008;28:37-45. (Pubitemid 350274399)
44. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 2005;27:64-77. (Pubitemid 40342577)
45. Osiri M, Suarez-Almazor ME, Wells GA, Robinson V, Tugwell P. Number needed to treat (NNT): Implication in rheumatology clinical practice. Ann Rheum Dis 2003;62:316-21. (Pubitemid 36363436)